U.S. markets closed

Atossa Therapeutics, Inc. (ATOS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.7400+0.1700 (+10.83%)
At close: 1:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Previous Close1.5700
Open1.5900
Bid1.7400 x 900
Ask1.7600 x 1400
Day's Range1.5700 - 1.7500
52 Week Range0.7600 - 5.0800
Volume308,358
Avg. Volume226,695
Market Cap18.257M
Beta (5Y Monthly)2.59
PE Ratio (TTM)N/A
EPS (TTM)-1.3780
Earnings DateNov 13, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.25
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Atossa Therapeutics Announces Third Quarter 2020 Financial Results and Provides Corporate Update
    GlobeNewswire

    Atossa Therapeutics Announces Third Quarter 2020 Financial Results and Provides Corporate Update

    SEATTLE, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, today announced financial results for the third quarter ended September 30, 2020, and provided an update on recent company developments.Key recent developments included: * Significantly advanced the development of AT-301 proprietary nasal spray as potential at-home treatment against COVID-19, with completion of a randomized, placebo controlled, double-blinded Phase 1 study and a preliminary assessment of the blinded data indicating that AT-301 was safe and well tolerated by participants at two different dose levels in both single and multiple dose forms over 14 days. * Applied for regulatory approval from the European Medical Product Authority to commence a Phase 2 clinical study of Endoxifen in Sweden to reduce mammographic breast density (MBD). * Announced interim findings following 18 months of an Expanded Access (or “compassionate use”) single-patient study of Endoxifen. The patient in the study had no cancer recurrence and suffered no side effects. Endoxifen did not cause other safety and tolerability concerns in this patient. “Our COVID-19 nasal spray program has progressed very well during the quarter, with our Phase 1 study of AT-301 nasal spray demonstrating good safety and tolerability at two different dose levels in both single and multiple dose forms over a 14-day trial period,” said Dr. Steven Quay, Atossa’s President and Chief Executive Officer. “We are very encouraged by these preliminary results. In the next 30 days we plan to file a pre-IND meeting request with the FDA and, subject to their input, plan to immediately commence a Phase 2 study, either in the U.S. or abroad, in patients recently diagnosed with COVID-19.“We believe AT-301 nasal spray is unique among the various therapies under development for COVID-19. While other companies are focused on therapies for patients being treated in hospitals, we are developing AT-301 for at-home use for the vast majority of COVID-19 patients who do not require hospitalization. Although great progress has been made by companies developing vaccines, it has become clear that a vaccine won’t provide a complete solution to the pandemic. No vaccine will be 100 percent effective and surveys have shown that many people won’t take a vaccine even when one becomes available. Similar to the seasonal flu where vaccines don’t provide complete community protection and people also rely on therapies, our AT-301 nasal spray therapy should form an important and necessary component of a comprehensive response to the COVID-19 pandemic,” added Dr. Quay.Upcoming 2020 milestones include the following: * File pre-IND meeting request with FDA for AT-301 nasal spray for potential at-home treatment of COVID-19. * Commence Phase 2 study in Sweden for our Endoxifen to reduce MBD. September 30, 2020 Financial Results For the three and nine months ended September 30, 2020 and 2019, we have no source of sustainable revenue and no associated cost of revenue.Operating Expenses: Total operating expenses were approximately $3,509,000 and $10,382,000 for the three and nine months ended September 30, 2020, respectively, consisting of R&D expenses of approximately $1,659,000 and $4,251,000, respectively, and general and administrative ("G&A") expenses of approximately $1,850,000 and $6,131,000, respectively. Total operating expenses were approximately $3,298,000 and $14,649,000 for the three and nine months ended September 30, 2019, respectively, consisting of R&D expenses of approximately $1,684,000 and $5,747,000, respectively, and G&A expense of approximately $1,614,000 and $8,901,000, respectively. Total operating expense for the nine months ended September 30, 2020 as compared to the same period in 2019 decreased approximately $4,267,000 or 29% and for the three months ended September 30, 2020 as compared to the same period in 2019 increased approximately $211,000 or 6%.Research and Development Expenses: R&D expenses for the three months ended September 30, 2020, were approximately $1,659,000, which were comparable to total R&D expenses for the three months ended September 30, 2019, of approximately $1,684,000. R&D expenses for the nine months ended September 30, 2020, were approximately $4,251,000, a decrease of approximately $1,496,000 or 26% from total R&D expenses for the nine months ended September 30, 2019, of approximately $5,747,000. The decrease in R&D expense is attributed primarily to a decrease in stock-based compensation of approximately $2,165,000, which is a non-cash charge, offset by an increase in salaries, professional fees and clinical trials expenses of approximately $669,000, as compared to the same period in 2019. We expect our R&D expenses to increase for the remainder of 2020 as we seek to commence a study of AT-H201, complete our Phase 1 study of AT-301, launch a Phase 2 clinical trial of Endoxifen in women with high breast density, and continue the development of other indications and therapeutics.General and Administrative Expenses: G&A expenses were approximately $1,850,000 for the three months ended September 30, 2020, an increase of approximately $236,000, or 15% from the total G&A expenses for the three months ended September 30, 2019, of approximately $1,614,000. The $236,000 increase in G&A expenses for the three month period ended September 30, 2020, is mainly attributed to an increase in legal, professional fees and insurance costs. G&A expenses were approximately $6,131,000 for the nine months ended September 30, 2020, a decrease of approximately $2,770,000, or 31% from the total G&A expenses for the nine months ended September 30, 2019, of approximately $8,901,000. G&A expenses consist primarily of personnel and related benefit costs, facilities, professional services, insurance, and public company related expenses. The decrease in G&A expenses for the nine month period ended September 30, 2020, is mainly attributed to a decrease in stock-based compensation expense of approximately $3,535,000, which is a non-cash charge, offset by an increase in legal, professional fees and insurance costs of approximately $765,000 compared to the same period in 2019. As of September 30, 2020, the Company had approximately $9.2 million in cash and cash equivalents.About Atossa TherapeuticsAtossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19. For more information, please visit www.atossatherapeutics.com.Forward-Looking StatementsForward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with any variation between interim and final clinical results, actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa including those needed to commence studies of AT-H201, AT-301 and Endoxifen, lower than anticipated rate of patient enrollment, estimated market size of drugs under development, the safety and efficacy of Atossa’s products, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others such as patent rights, whether reduction in Ki-67 or any other result from a neoadjuvant study is an approvable endpoint for oral Endoxifen, and other risks detailed from time to time in Atossa’s filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.Company Contact: Atossa Therapeutics, Inc. Kyle Guse CFO and General Counsel Office: 866 893-4927 kyle.guse@atossainc.comInvestor Relations Contact: Core IR Office:(516) 222-2560 ir@atossainc.comSource: Atossa Therapeutics, Inc. ATOSSA THERAPEUTICS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS  As of September 30, 2020  As of December 31,  Assets (Unaudited)  2019  Current assets         Cash and cash equivalents $9,105,950  $12,581,136  Restricted cash  110,000   110,000  Prepaid expenses  1,484,251   862,344  Research and development tax rebate receivable  439,205   739,656  Other current assets  178,911   26,130  Total current assets  11,318,317   14,319,266            Furniture and equipment, net  25,429   34,350  Intangible assets, net  45,417   68,542  Right-of-use asset  31,279   50,479  Other assets  17,218   17,218  Total Assets $11,437,660  $14,489,855            Liabilities and Stockholders' Equity         Current liabilities         Accounts payable $682,612  $293,171  Accrued expenses  85,173   77,888  Payroll liabilities  752,847   899,420  Lease liability  30,063   39,371  Other current liabilities  14,671   12,892  Total current liabilities  1,565,366   1,322,742  Long term liabilities         Lease liability long term  1,217   11,108  Total Liabilities  1,566,583   1,333,850            Commitments and contingencies                   Stockholders' equity         Preferred stock - $0.001 par value; 10,000,000 shares authorized; 623 and 671 shares issued and outstanding as of September 30, 2020 and December 31, 2019, respectively  1   1  Additional paid-in capital - Series B convertible preferred stock  622,999   670,999  Common stock - $0.18 par value; 175,000,000 shares authorized; 10,464,250 and 9,130,984 shares issued and outstanding as of September 30, 2020 and December 31, 2019, respectively  1,883,553   1,643,565  Additional paid-in capital  111,780,197   104,912,480  Accumulated deficit  (104,415,673)  (94,071,040) Total Stockholders' Equity  9,871,077   13,156,005  Total Liabilities and Stockholders' Equity $11,437,660  $14,489,855  The accompanying notes are an integral part of these condensed consolidated financial statements. ATOSSA THERAPEUTICS, INC.  CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)  For the Three Months Ended September 30,  For the Nine Months Ended September 30,                      2020  2019  2020  2019  Operating expenses                 Research and development $1,659,075  $1,684,215  $4,250,934  $5,747,399  General and administrative  1,849,741   1,613,983   6,130,698   8,901,197  Total operating expenses  3,508,816   3,298,198   10,381,632   14,648,596  Operating loss  (3,508,816)  (3,298,198)  (10,381,632)  (14,648,596) Other income  17,745   12,284   36,999   26,846  Loss before income taxes  (3,491,071)  (3,285,914)  (10,344,633)  (14,621,750) Income taxes  -   -   -   -  Net loss $(3,491,071) $(3,285,914) $(10,344,633) $(14,621,750) Loss per common share - basic and diluted $(0.34) $(0.36) $(1.09) $(1.77) Weighted average shares outstanding - basic and diluted  10,162,770   9,130,057   9,496,222   8,283,302  The accompanying notes are an integral part of these condensed consolidated financial statements.

  • Atossa Therapeutics Announces Preliminary Results from Phase 1 Clinical Study Showing Safety and Tolerability of AT-301 Nasal Spray Being Developed for COVID-19
    GlobeNewswire

    Atossa Therapeutics Announces Preliminary Results from Phase 1 Clinical Study Showing Safety and Tolerability of AT-301 Nasal Spray Being Developed for COVID-19

    SEATTLE, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, today announced blinded preliminary results from its Phase 1 clinical study using Atossa’s proprietary drug candidate AT-301 administered by nasal spray. AT-301 was found to be safe and well tolerated in this study at two different dose levels in both single and multiple dose forms over 14 days. AT-301 is being developed for at home use for patients recently diagnosed with COVID-19. There are currently no FDA-approved therapies to treat COVID-19 at home. “We have completed all dosing in this study and we have now evaluated the blinded safety and tolerability data from all participants,” commented Steven Quay, M.D., Ph.D., Atossa’s President and CEO. “There we no serious adverse events, no discontinuations, and only one subject of the 32 subjects in the study experienced adverse events that were considered moderate in severity and all other adverse events were considered mild. Our preliminary assessment is that our AT-301 nasal spray was safe and well tolerated in this study. These results support advancing this program into a Phase 2 study. We are in the process of preparing a pre-IND meeting request with the U.S. FDA which we plan to submit in the next 30 days.”Atossa plans to identify potential partners who are developing COVID-19 diagnostic tests so that AT-301 nasal spray may be co-developed and commercialized with the goal of making the AT-301 therapy available at the time a person tests positive for the coronavirus. Atossa also plans to develop its nasal spray to potentially help prevent COVID-19 infection -- particularly for people in high risk environments -- including, for example, people living with a patient infected with COVID-19, healthcare workers, emergency responders and teachers.  While other companies continue to develop a vaccine for SARS-CoV-2, Atossa believes that a significant market opportunity exists for therapies like AT-301. A traditional vaccine may still take years to develop and become widely available. Surveys have shown that many people will not take a vaccine when it is initially available and a traditional vaccine will likely not be 100% effective, particularly if different strains of the Coronavirus emerge.The Phase 1 study is a double-blinded, randomized, and placebo-controlled safety study of AT-301 nasal spray in 32 healthy adult subjects who were divided into two study groups. Part A consists of two single-dose cohorts receiving either active therapy, AT-301B, or the placebo comparator AT-301A at two different doses. Part B is a multiple dose arm with cohorts receiving either AT-301A or AT-301B for 14 days at two different doses. The primary objective of the study is to evaluate the safety and tolerability of single and multiple doses of AT-301 administered via nasal instillation to healthy volunteers. Secondary objectives are to assess the incidence and severity of local irritation and bronchospasm following administration of AT-301 via nasal instillation. The study is being conducted in Australia.About Atossa TherapeuticsAtossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19. For more information, please visit www.atossatherapeutics.comForward-Looking StatementsForward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with development plans, any variation between interim, preliminary and final clinical results, actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa including those needed to commence studies of AT-H201, AT-301 and Endoxifen, lower than anticipated rate of patient enrollment, estimated market size of drugs under development, the safety and efficacy of Atossa’s products, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others such as patent rights, whether reduction in Ki-67 or any other result from a neoadjuvant study is an approvable endpoint for oral Endoxifen, and other risks detailed from time to time in Atossa’s filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.Company Contact: Atossa Therapeutics, Inc. Kyle Guse, CFO and General Counsel Office: (866) 893-4927 kyle.guse@atossainc.comInvestor Relations Contact: Core IR Office:(516) 222-2560 ir@atossainc.comSource: Atossa Therapeutics, Inc.